Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder that destroys patient memory and cognition, communication ability with the social environment and the ability to carry out daily activities. Despite extensive research into the pathogenesis of AD, a neuroprotective treatment - particularly for the early stages of disease - remains unavailable for clinical use. In this review, we advance the suggestion that lipoic acid (LA) may fulfil this therapeutic need. A naturally occurring cofactor for the mitochondrial enzymes pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, LA has been shown to have a variety of properties which can interfere with the pathogenesis or progression of AD. For example, LA increases acetylcholine (ACh) production by activation of choline acetyltransferase and increases glucose uptake, thus supplying more acetyl-CoA for the production of ACh. LA chelates redox-active transition metals, thus inhibiting the formation of hydroxyl radicals and also scavenges reactive oxygen species (ROS), thereby increasing the levels of reduced glutathione. In addition, LA down-regulates the expression of redox-sensitive pro-inflammatory proteins including TNF and inducible nitric oxide synthase. Furthermore, LA can scavenge lipid peroxidation products such as hydroxynonenal and acrolein. In human plasma, LA exists in an equilibrium of free and plasma protein bound form. Up to 150 muM, it is bound completely, most likely binding to high affinity fatty acid sites on human serum albumin, suggesting that one large dose rather than continuous low doses (as provided by "slow release" LA) will be beneficial for delivery of LA to the brain. Evidence for a clinical benefit for LA in dementia is yet limited. There are only two published studies, in which 600 mg LA was given daily to 43 patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of up to 48 months. Whereas the improvement in patients with moderate dementia was not significant, the disease progressed extremely slowly (change in ADAScog: 1.2 points=year, MMSE: -0.6 points=year) in patients with mild dementia (ADAScog<15). Data from cell culture and animal models suggest that LA could be combined with nutraceuticals such as curcumin, (-)-epigallocatechin gallate (from green tea) and docosahexaenoic acid (from fish oil) to synergistically decrease oxidative stress, inflammation, Abeta levels and Abeta plaque load and thus provide a combined benefit in the treatment of AD.

The Effects and Mechanisms of Mitochondrial Nutrient Α-Lipoic Acid on Improving Age-Associated Mitochondrial and Cognitive Dysfunction: an Overview

Mitochondrial Decay in the Brains of Old Rats: Ameliorating Effect of Alpha-Lipoic Acid and Acetyl-L-Carnitine

Reducing Mitochondrial Decay with Mitochondrial Nutrients to Delay and Treat Cognitive Dysfunction, Alzheimer's Disease, and Parkinson's Disease

L-arginine Metabolism Ameliorates Age-Related Cognitive Impairment by Amuc_1100-mediated Gut Homeostasis Maintaining

Delaying Brain Mitochondrial Decay and Aging with Mitochondrial Antioxidants and Metabolites

Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats.

Delaying the Mitochondrial Decay of Aging with Acetylcarnitine.

Age-associated Mitochondrial Oxidative Decay: Improvement of Carnitine Acetyltransferase Substrate-Binding Affinity and Activity in Brain by Feeding Old Rats Acetyl- L - Carnitine And/or R -Α-lipoic Acid

Memory Loss in Old Rats is Associated with Brain Mitochondrial Decay and RNA/DNA Oxidation: Partial Reversal by Feeding Acetyl-L-carnitine And/or R-alpha -Lipoic Acid.

Targeting Mitochondria with Exercise and Nutrients:A New Strategy for the Prevention of Alzheimer Disease

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease

Age-associated mitochondrial oxidative decay: Improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl- <scp>l</scp> - carnitine and/or <i>R</i> -α-lipoic acid

Combined R-alpha-lipoic Acid and Acetyl-L-carnitine Exerts Efficient Preventative Effects in a Cellular Model of Parkinson's Disease.

(R)-α-Lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate

Improving Mitochondrial Function for Alleviating Memory Decline of Aging Mice Via Dual-Delivering Lycopene Nanoparticles

Dietary Mitophagy Enhancer: A Strategy for Healthy Brain Aging?

A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions

Role of Combined Lipoic Acid and Vitamin D3 on Astrocytes as a Way to Prevent Brain Ageing by Induced Oxidative Stress and Iron Accumulation

Exercise-Induced Benefits for Alzheimer’s Disease by Stimulating Mitophagy and Improving Mitochondrial Function

Enhancing healthy aging with small molecules: A mitochondrial perspective

Effectiveness and mechanisms of combined use of antioxidant nutrients in protecting against oxidative stress-induced neuronal loss and related neurological deficits